60 related articles for article (PubMed ID: 25818616)
1. BRAF and CDKN2A mutations in secondary high-grade glioma.
Boughton B
Lancet Oncol; 2015 May; 16(5):e201. PubMed ID: 25818616
[No Abstract] [Full Text] [Related]
2. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
3. Malignant transformation of low-grade gliomas in children: lessons learned from rare medical events.
Broniscer A
J Clin Oncol; 2015 Mar; 33(9):978-9. PubMed ID: 25667289
[No Abstract] [Full Text] [Related]
4. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
5. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
[TBL] [Abstract][Full Text] [Related]
6. BRAF-Targeted Therapy in the Treatment of
Johanns TM; Ansstas G; Dahiya S
J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
[No Abstract] [Full Text] [Related]
7. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
8. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro.
Chintala SK; Fueyo J; Gomez-Manzano C; Venkaiah B; Bjerkvig R; Yung WK; Sawaya R; Kyritsis AP; Rao JS
Oncogene; 1997 Oct; 15(17):2049-57. PubMed ID: 9366522
[TBL] [Abstract][Full Text] [Related]
10. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
[No Abstract] [Full Text] [Related]
11. Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination.
Chiang JCH; Harreld JH; Orr BA; Sharma S; Ismail A; Segura AD; Ellison DW
Acta Neuropathol; 2017 Jul; 134(1):159-162. PubMed ID: 28547128
[No Abstract] [Full Text] [Related]
12. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
13. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
[TBL] [Abstract][Full Text] [Related]
14. New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis?
Tabouret E; Fina F; Vincentelli F; Nanni I; Figarella-Branger D
J Neurol Sci; 2014 Jul; 342(1-2):204-6. PubMed ID: 24857351
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
16. A low-grade malignant soft tissue tumor with S100 and CD34 co-expression showing novel CDC42SE2-BRAF fusion with distinct features.
Sheng SJ; Li JM; Zou YF; Peng XJ; Wang QY; Fang HS; Li X; Ding Y; Fan QH; Zhang ZH; Wei YZ; Gong QX
Genes Chromosomes Cancer; 2020 Oct; 59(10):595-600. PubMed ID: 32447786
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression.
Yazdan P; Cooper C; Sholl LM; Busam K; Rademaker A; Weitner BB; Obregon R; Guitart J; Gerami P
Am J Surg Pathol; 2014 May; 38(5):638-45. PubMed ID: 24451276
[TBL] [Abstract][Full Text] [Related]
18. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
